Termination of disease-modifying antirheumatic drugs in rheumatoid arthritis and in psoriatic arthritis. A comparative study of 270 cases

I. Újfalussy, É Koó, M. Seszták, P. Gergely

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

102 rheumatoid arthritis (RA) and 104 psoriatic arthritis (PsA) patients' records were analysed according to a standardised protocol. Using Cox regression, life-table analysis and log rank test, the effectiveness and toxicity of, and duration of disease modifying antirheumatic drug (DMARD) treatment were compared in RA and PsA. RA patients were treated with gold sodium thiomalate (GST), methotrexate (MTX) and sulphasalazine (SSZ) for a median duration of 35, 72 and 12 months respectively, whereas PsA patients were treated for 12, 12 and 17 months. The differences for GST and MTX were statistically significant (p = 0.0043 and 0.0447). Drug toxicity was more frequently seen among patients with PsA (p = 0.0023). No difference in efficacy could be proved. Results suggest that there is a significant difference between RA and PsA patients in terms of toxicity of these agents. Therefore, separate treatment strategies are needed, and earlier results with RA may not be directly applicable to PsA.

Original languageEnglish
Pages (from-to)155-160
Number of pages6
JournalZeitschrift fur Rheumatologie
Volume62
Issue number2
DOIs
Publication statusPublished - Apr 2003

Fingerprint

Psoriatic Arthritis
Antirheumatic Agents
Rheumatoid Arthritis
Gold Sodium Thiomalate
Methotrexate
Toxicity Tests
Sulfasalazine
Life Tables
Drug-Related Side Effects and Adverse Reactions
Therapeutics

Keywords

  • Disease modifying antirheumatic drugs
  • Life table analysis
  • Psoriatic arthritis
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Rheumatology

Cite this

Termination of disease-modifying antirheumatic drugs in rheumatoid arthritis and in psoriatic arthritis. A comparative study of 270 cases. / Újfalussy, I.; Koó, É; Seszták, M.; Gergely, P.

In: Zeitschrift fur Rheumatologie, Vol. 62, No. 2, 04.2003, p. 155-160.

Research output: Contribution to journalArticle

@article{54bd1a07fd3e4ac590a958f6626ca90d,
title = "Termination of disease-modifying antirheumatic drugs in rheumatoid arthritis and in psoriatic arthritis. A comparative study of 270 cases",
abstract = "102 rheumatoid arthritis (RA) and 104 psoriatic arthritis (PsA) patients' records were analysed according to a standardised protocol. Using Cox regression, life-table analysis and log rank test, the effectiveness and toxicity of, and duration of disease modifying antirheumatic drug (DMARD) treatment were compared in RA and PsA. RA patients were treated with gold sodium thiomalate (GST), methotrexate (MTX) and sulphasalazine (SSZ) for a median duration of 35, 72 and 12 months respectively, whereas PsA patients were treated for 12, 12 and 17 months. The differences for GST and MTX were statistically significant (p = 0.0043 and 0.0447). Drug toxicity was more frequently seen among patients with PsA (p = 0.0023). No difference in efficacy could be proved. Results suggest that there is a significant difference between RA and PsA patients in terms of toxicity of these agents. Therefore, separate treatment strategies are needed, and earlier results with RA may not be directly applicable to PsA.",
keywords = "Disease modifying antirheumatic drugs, Life table analysis, Psoriatic arthritis, Rheumatoid arthritis",
author = "I. {\'U}jfalussy and {\'E} Ko{\'o} and M. Seszt{\'a}k and P. Gergely",
year = "2003",
month = "4",
doi = "10.1007/s00393-003-0458-2",
language = "English",
volume = "62",
pages = "155--160",
journal = "Zeitschrift fur Rheumatologie",
issn = "0340-1855",
publisher = "D. Steinkopff-Verlag",
number = "2",

}

TY - JOUR

T1 - Termination of disease-modifying antirheumatic drugs in rheumatoid arthritis and in psoriatic arthritis. A comparative study of 270 cases

AU - Újfalussy, I.

AU - Koó, É

AU - Seszták, M.

AU - Gergely, P.

PY - 2003/4

Y1 - 2003/4

N2 - 102 rheumatoid arthritis (RA) and 104 psoriatic arthritis (PsA) patients' records were analysed according to a standardised protocol. Using Cox regression, life-table analysis and log rank test, the effectiveness and toxicity of, and duration of disease modifying antirheumatic drug (DMARD) treatment were compared in RA and PsA. RA patients were treated with gold sodium thiomalate (GST), methotrexate (MTX) and sulphasalazine (SSZ) for a median duration of 35, 72 and 12 months respectively, whereas PsA patients were treated for 12, 12 and 17 months. The differences for GST and MTX were statistically significant (p = 0.0043 and 0.0447). Drug toxicity was more frequently seen among patients with PsA (p = 0.0023). No difference in efficacy could be proved. Results suggest that there is a significant difference between RA and PsA patients in terms of toxicity of these agents. Therefore, separate treatment strategies are needed, and earlier results with RA may not be directly applicable to PsA.

AB - 102 rheumatoid arthritis (RA) and 104 psoriatic arthritis (PsA) patients' records were analysed according to a standardised protocol. Using Cox regression, life-table analysis and log rank test, the effectiveness and toxicity of, and duration of disease modifying antirheumatic drug (DMARD) treatment were compared in RA and PsA. RA patients were treated with gold sodium thiomalate (GST), methotrexate (MTX) and sulphasalazine (SSZ) for a median duration of 35, 72 and 12 months respectively, whereas PsA patients were treated for 12, 12 and 17 months. The differences for GST and MTX were statistically significant (p = 0.0043 and 0.0447). Drug toxicity was more frequently seen among patients with PsA (p = 0.0023). No difference in efficacy could be proved. Results suggest that there is a significant difference between RA and PsA patients in terms of toxicity of these agents. Therefore, separate treatment strategies are needed, and earlier results with RA may not be directly applicable to PsA.

KW - Disease modifying antirheumatic drugs

KW - Life table analysis

KW - Psoriatic arthritis

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=0038246439&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038246439&partnerID=8YFLogxK

U2 - 10.1007/s00393-003-0458-2

DO - 10.1007/s00393-003-0458-2

M3 - Article

VL - 62

SP - 155

EP - 160

JO - Zeitschrift fur Rheumatologie

JF - Zeitschrift fur Rheumatologie

SN - 0340-1855

IS - 2

ER -